期刊文献+

胃食管交界腺癌术后静态IMRT、VMAT和HT剂量学比较 被引量:1

A dosimetric comparison of static intensity-modulated radiotherapy, volumetric-modulated arc therapy, and helical tomotherapy after surgery for gastroesophageal junction adenocarcinoma
原文传递
导出
摘要 目的评价胃食管交界腺癌根治术后不同照射技术对靶区和正常组织剂量分布的影响,为临床治疗方法提供优选方案。方法对9例行根治性食管近端胃切除术或全胃切除术后的胃食管交界腺癌患者分别进行5个野静态IMRT、双弧VMAT和HT计划设计.通过DVH评价不同照射技术对靶区CI、HI和对OAR受量影响。放疗剂量45Gy(1.8Gy/次),同期每天口服替吉奥80mg/m2。放疗日分2次口服。结果HT靶区CI和HI好于IMRT和VMAT。对肠道和骨髓保护HT亦优于IMRT和VMAT。VMAT左肾V20、V30和心脏V30低于IMRT和HT,而IMRT双肺V5、V10较低;V20和Dmean三种技术差异不大。子野跳数平均数VMAT〈IMRT〈HT。结论3种放疗技术均能较好达到临床要求,但HT在保证最好靶区CI、HI前提下,对小肠和脊髓保护方面有优势,可能有助于降低患者相关不良反应发生。 Objective To investigate the effects of different irradiation techniques on dose distribution in target volume and normal tissues after the radical surgery for gastroesophageal junction adenocarcinoma,and to provide the optimal regimen for clinical treatment. Methods A total of 9 patients with gastroesophageal junction adenocarcinoma who underwent radical esophagus-proximal gastrectomy or total gastrectomy were enrolled. The therapeutic regimens of five-field static intensity-modulated radiotherapy (IMRT), volumetric-modulated arc therapy (VMAT), and helical tomotherapy (HT) were designed for each patient, and the dose-volume histogram was used to evaluate the effects of different irradiation techniques on the conformity index (CI) and homogeneity index (HI) of target volume and the surrounding normal tissues. The prescribed dose was 45 Gy at 1.8 Gy/fraction. The patients received oral S-1 as concurrent chemotherapy at a dose of 80 rag/( m2 ~ d) twice a day during radiotherapy. Results Compared with IMRT and VMAT, HT had better CI and HI of the target volume,as well as a better protective effect on the intestinal tract and bone marrow. Compared with IMRT and HT,VMAT had a lower V20 and V30 for the left kidney and a lower V30 for the heart, while IMRT had lower V5 and V10 for both lungs;V20 and mean dose showed no significant differences between the three techniques. HT had the highest mean sub-field hop count, followed by IMRT and VMAT. Conclusions IMRT, VMAT, and HT can meet the clinical requirements, but besides ensuring the best CI and HI of the target volume, HT has a good protective effect on the intestine and spinal cord and' can help to reduce the incidence of adverse events in patients.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2016年第3期255-259,共5页 Chinese Journal of Radiation Oncology
关键词 胃食管交界肿瘤/放射疗法 螺旋断层疗法 调强放射疗法 容积调强弧形疗法 剂量学 Gastroesophageal junction neoplasms/radiotherapy Helical tomotherapy Intensity- modulated radiotherapy Volumetric-modulated arc therapy Dosimetry
  • 相关文献

参考文献23

  • 1DeSantis CE,Lin CC,Mariotto AB,et al. Cancer treatment and survivorship statistics,2014[J].CA Cancer J Clin,2014,64(4):252-271.DOI:10.3322/caac.21235.
  • 2NCCN guidelines panel. National comprehensive cancer network guidelines in oncology (NCCN guidelines).Esophageal and esophagogastric junction cancers.2015.Version 3,2015-03-23[DB/OL].
  • 3Japanese classification of gastric carcinoma:3rd English edition[J].Gastric Cancer,2011,14(2):101-112.DOI:10.1007/s10120-011-0041-5.
  • 4Mell LK,Kochanski JD,Roeske JC,et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,66(5):1356-1365.DOI:10.1016/j.ijrobp.2006.03.018.
  • 5Smalley SR,Benedetti JK,Haller DG,et al. Updated analysis of SWOG-directed intergroup study 0116:a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J].J Clin Oncol,2012,30(19):2327-2333.DOI:10.1200/JCO.2011.36.7136.
  • 6Macdonald JS,Smalley SR,Benedetti J,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J].N Engl J Med,2001, 345(10):725-730. DOI:10.1056/NEJMoa010187.
  • 7Lee J,Lim do H,Kim S,et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial[J].J Clin Oncol,2012,30(3):268-273.DOI:10.1200/JCO.2011.39.1953.
  • 8Park SH,Sohn TS,Lee J,et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer:final report of the adjuvant chemoradiotherapy in stomach tumors trial,including survival and subset analyses[J].J Clin Oncol,2015,33(28):3130-3136.DOI:10.1200/JCO.2014.58.3930.
  • 9王鑫,金晶,李晔雄,王淑莲,刘跃平,王维虎,房辉,任骅,宋永文,刘新帆,余子豪.局部晚期胃癌术后卡培他滨同期调强放疗的I期临床研究[J].中华放射肿瘤学杂志,2013,22(5):343-346. 被引量:9
  • 10Hu W,Wang J,Li G,et al. Investigation of plan quality between RapidArc and IMRT for gastric cancer based on a novel beam angle and multicriteria optimization technique[J].Radiother Oncol,2014,111(1):144-147.DOI:10.1016/j.radonc.2014.01.024.

二级参考文献21

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin,2011,61:69-90.
  • 2贺捷,陈万青.2012巾国肿瘤登记年报.北京:军事医学科学出版社,2012.
  • 3Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med,2001,345 :725-730.
  • 4National Comprehensive Cancer Network ( NCCN ). NCCN Guidelines in Oncology. Gastric cancer. Version 2. 2011 [ 2013-04-20 ]. http ://www. wenkudaquan, corrt/doc/20120 927/671686. html.
  • 5Solomon NL, Cheung MC, Byrne MM, et al. Does chemoradiotherapy improve outcomes for surgically resectedadenocarcinoma of the stomach or esophagus? Ann Surg Oncol, 2010,17:98-108.
  • 6Lee J, Limdo H, Kim S, et al. Phase llI trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol, 2012,30 : 268 -273.
  • 7Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy ( CLASSIC ) : a phase 3 open-label, randomised controlled trial. Lancet, 2012, 379:315-321.
  • 8Kang YK, Kang WK, Shin DB, et al. Capecitabine-cisplatin versus 5-fluorouracil/cisplatin as first-llne therapy in patients withadvanced gastric cancer: a randomizedPhase m noninferiority trial. Ann. Oncol,2009,20:666-673.
  • 9American Joint Committee on Cancer. AJCC cancer stage manual. senven edition [2013-04-201. http://www, docin, corn/p- 250275013. html#documentinfo.
  • 10Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English edition. Gastric Cancer, 1998,1 : 10-24.

共引文献8

同被引文献10

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部